Tocainide

Tocainide

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601248
ATC code	C01BB03 (WHO)
Pharmacokinetic data
Bioavailability	0.9-1 (oral)
Protein binding	10-20%
Metabolism	glucuronidation (primary)
Elimination half-life	9-14 R, 13-20 S
Excretion	30-50% urine (unchanged)
Identifiers
IUPAC name N-(2,6-dimethylphenyl)alaninamide
CAS Number	41708-72-9 Y
PubChem CID	38945
DrugBank	DB01056 Y
ChemSpider	35632 Y
UNII	27DXO59SAN
KEGG	D06172 Y
ChEBI	CHEBI:9611 Y
ChEMBL	ChEMBL1762 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H16N2O
Molar mass	192.258 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(Nc1c(cccc1C)C)C(N)C
InChI InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14) Y Key:BUJAGSGYPOAWEI-UHFFFAOYSA-N Y
(verify)

WikiDoc Resources for Tocainide
Articles
Most recent articles on Tocainide Most cited articles on Tocainide Review articles on Tocainide Articles on Tocainide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tocainide Images of Tocainide Photos of Tocainide Podcasts & MP3s on Tocainide Videos on Tocainide
Evidence Based Medicine
Cochrane Collaboration on Tocainide Bandolier on Tocainide TRIP on Tocainide
Clinical Trials
Ongoing Trials on Tocainide at Clinical Trials.gov Trial results on Tocainide Clinical Trials on Tocainide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tocainide NICE Guidance on Tocainide NHS PRODIGY Guidance FDA on Tocainide CDC on Tocainide
Books
Books on Tocainide
News
Tocainide in the news Be alerted to news on Tocainide News trends on Tocainide
Commentary
Blogs on Tocainide
Definitions
Definitions of Tocainide
Patient Resources / Community
Patient resources on Tocainide Discussion groups on Tocainide Patient Handouts on Tocainide Directions to Hospitals Treating Tocainide Risk calculators and risk factors for Tocainide
Healthcare Provider Resources
Symptoms of Tocainide Causes & Risk Factors for Tocainide Diagnostic studies for Tocainide Treatment of Tocainide
Continuing Medical Education (CME)
CME Programs on Tocainide
International
Tocainide en Espanol Tocainide en Francais
Business
Tocainide in the Marketplace Patents on Tocainide
Experimental / Informatics
List of terms related to Tocainide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tocainide (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.

Pharmacokinetics

Tocainide is a lidocaine analog, that does not have significant 1st pass metabolism. It is found in two enantiomers. The R isomer is 4x as potent as the S. Oral bioavailability is 0.9-1.0. In the blood tocainide is 10-20% protein bound. The Volume of distribution is 2.5-3.5 L/kg. 30-50% is excreted unchanged in the urine. The more active R-isomer is cleared faster in anephric patients or those with severe renal dysfunction. The main metabolite is the glucuronidated tocainide carbamic acid. The glucuronosyl transferase is apparently induced by rifampin. Weak inhibition of Cyp1A2 leads to a mild theophylline interaction.